Source link : https://newshealth.biz/health-news/triplet-could-become-a-new-standard-in-tough-to-treat-cll/
Fixed-duration therapy with pirtobrutinib (Jaypirca) plus venetoclax (Venclexta) and rituximab improved progression-free survival (PFS) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), according to interim data from the phase III BRUIN CLL-322 trial. In the intent-to-treat population, median PFS was not estimable with the triplet therapy versus 39.7 months with venetoclax and rituximab, with independent […]
The post Triplet Could Become a New Standard in Tough-to-Treat CLL first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-17 16:32:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8